FIGURE 5 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Expression of protein markers significantly altered by treatment with eribulin in combination with copanlisib in three eribulin-resistant models (WHIM3, WHIM4, and WHIM6). Expression of indicated RPPA protein markers are shown. AuroraₚT288ₚT232ₚT198, and Histone H3ₚS10, were significantly upregulated, with FDR-adjusted P value